Impact of Dupilumab on Small Airway Disease in Severe Asthma: A 12-Month Retrospective Real-World Study - PubMed
8 hours ago
- #Small Airway Disease
- #Severe Asthma
- #Dupilumab
- The study evaluated dupilumab's impact on small-airway disease (SAD) in severe asthma over 12 months.
- 62% of the 21 patients had SAD at baseline (R5-R20 > 0.07 kPa/L/s).
- Dupilumab significantly improved small-airway function: R5-R20 decreased from 0.18 to 0.09 kPa/L/s, and predicted FEF25-75% increased from 29.5% to 47.0%.
- Asthma Control Test scores improved from 13.1 to 19.6, and FeNO levels decreased from 64.1 to 24.8 ppb.
- Improvements in R5-R20 correlated with better asthma control and reduced type 2 inflammation.
- Treatment also reduced exacerbation frequency and oral corticosteroid dependence.